Compare Ascendis Pharma A/S (ASND) vs Elastic NV (ESTC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Elastic NV — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Elastic NV trades at $59.95 (market cap $6.26B). The key difference: Ascendis Pharma A/S is far larger — about 2.8× Elastic NV's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Elastic NV nearer its low. Which is the better fit depends on your goals.
| ASND | ESTC | |
|---|---|---|
Market Cap | $17.74B | $6.26B |
Sector | Health | Technology |
52-Week High | $277.18 | $94.47 |
52-Week Low | $163.32 | $43.30 |
Enterprise Value | $18.11B | $5.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Elastic (ESTC) trades at $60.24, down 2.93% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $72.80. The company shows strong revenue growth, improving profitability into 2026, and consistent earnings beats, while recent news highlights leadership in security and observability markets.
The stock presents a growth opportunity with robust fundamentals and positive analyst sentiment, though risks include high valuation multiples, ongoing legal scrutiny, and competitive pressures in the software sector that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Elastic NV
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →
